Provided by Tiger Fintech (Singapore) Pte. Ltd.

Sutro Biopharma Inc

0.7669
-0.0291-3.66%
Post-market: 0.79010.0232+3.03%19:42 EDT
Volume:1.78M
Turnover:1.40M
Market Cap:64.25M
PE:-0.26
High:0.8209
Open:0.7900
Low:0.7669
Close:0.7960
Loading ...

Sutro Biopharma Announces Selected Dose for Luvelta and Topline Results from Dose-Optimization Portion of REFRαME-O1 Trial in Platinum Resistant Ovarian Cancer

GlobeNewswire
·
10 Dec 2024

Why Investors Shouldn't Be Surprised By Sutro Biopharma, Inc.'s (NASDAQ:STRO) 26% Share Price Plunge

Simply Wall St.
·
30 Nov 2024

Sutro Biopharma (STRO) Upgraded to Buy: Here's What You Should Know

Zacks
·
19 Nov 2024

Sutro Biopharma Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Nov 2024

Sutro Biopharma (STRO) Receives a Buy from Truist Financial

TIPRANKS
·
15 Nov 2024

Sutro Biopharma Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.
·
15 Nov 2024

Sutro Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
14 Nov 2024

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Misses Revenue Estimates

Zacks
·
14 Nov 2024

Sutro Biopharma Q3 EPS $(0.59) Beats $(0.73) Estimate, Sales $8.52M Miss $15.25M Estimate

Benzinga
·
14 Nov 2024

BRIEF-Sutro Biopharma Q3 Revenue USD 8.52 Million

Reuters
·
14 Nov 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

THOMSON REUTERS
·
14 Nov 2024

Sutro Biopharma Q3 Operating Expenses USD 76.439 Million

THOMSON REUTERS
·
14 Nov 2024

Sutro Biopharma Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire
·
14 Nov 2024

Sutro Biopharma Inc expected to post a loss of 73 cents a share - Earnings Preview

Reuters
·
08 Nov 2024

Sutro Biopharma Demonstrates Meaningful ADC Innovation with Five Presentations at the 15th Annual World ADC Conference

GlobeNewswire
·
05 Nov 2024

Sutro Biopharma Opens Enrollment for Luveltamab Tazevibulin Trial

MT Newswires Live
·
01 Nov 2024